###begin article-title 0
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Despite identification of the major genes and pathways involved in the development of colorectal cancer (CRC), it has become obvious that several steps in these pathways might be bypassed by other as yet unknown genetic events that lead towards CRC. Therefore we wanted to improve our understanding of the genetic mechanisms of CRC development.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
We used microarrays to identify novel genes involved in the development of CRC. Real time PCR was used for mRNA expression as well as to search for chromosomal abnormalities within candidate genes. The correlation between the expression obtained by real time PCR and the presence of the KRAS mutation was investigated.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
We detected significant previously undescribed underexpression in CRC for genes SLC26A3, TPM1 and DCN, with a suggested tumour suppressor role. We also describe the correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC. When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case of CRC, but no deletions of DCN and SLC26A3 were found.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 480 484 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 550 554 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Our study provides further evidence of decreased mRNA expression of three important tumour suppressor genes in cases of CRC, thus implicating them in the development of this type of cancer. Moreover, we found underexpression of the TPM1 gene in a case of CRCs without KRAS mutations, showing that TPM1 might serve as an alternative path of development of CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the other hand, the correlation of DCN underexpression with the presence of KRAS mutations suggests that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount of the important tumour suppressor protein decorin.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH2</italic>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2 </italic>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH6</italic>
###xml 847 852 847 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 915 916 915 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 932 937 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD2</italic>
###xml 939 944 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4</italic>
###xml 946 949 946 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC</italic>
###xml 1014 1015 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1054 1057 1054 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 1107 1108 1107 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1202 1203 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1385 1386 1385 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1424 1428 1424 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 1430 1434 1430 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH2</italic>
###xml 1436 1440 1436 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2</italic>
###xml 1442 1447 1442 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH6 </italic>
###xml 1709 1710 1709 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1711 1712 1711 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1755 1758 1755 1758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 1760 1764 1760 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1768 1773 1768 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1843 1844 1843 1844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1908 1912 1908 1912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 2046 2051 2046 2051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 2070 2071 2070 2071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 2072 2074 2072 2074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 64 67 <span type="species:ncbi:9606">men</span>
###xml 72 77 <span type="species:ncbi:9606">women</span>
###xml 2029 2037 <span type="species:ncbi:9606">patients</span>
Colorectal cancer (CRC) is the third most common cancer in both men and women [1]. It remains one of the most frequent and deadly diseases [1] despite important advantages in treatment and diagnosis [2]. The evolution from normal colonic mucosa to adenoma with different grades of dysplasia and finally to invasive cancer is associated with a series of genetic events occurring over a long period [3]. Not surprisingly, the incidence of colorectal cancer increases with age, especially after 60 years. Two pathways have been proposed for colorectal cancer development. The microsatellite instability (MSI) pathway is caused by mutations in genes MLH1, MSH2, PMS2 and MSH6, which are part of the mismatch repair system. The chromosomal instability (CIN) pathway is associated with mutations in the APC gene or loss of 5q (APC) and mutations in the KRAS gene during progression of normal epithelium to early adenoma [4]. Loss of 18q (SMAD2, SMAD4, DCC) is associated with progression from early to advanced adenoma [4]. Deletion of 17p, which contains the p53 gene, is involved in progression towards cancer [4]. However, only a minority of CRCs possess a full spectrum of these molecular abnormalities [5]. Moreover, even though major genes involved in the development of colorectal cancer have been identified, interestingly most of them have shown only limited value in clinical use [6]. Detection of germline mutations in MLH1, MSH2, PMS2, MSH6 and APC is used to identify individuals with a predisposition for developing hereditary nonpolyposis colon cancer (HNPCC) and familial adenomatous polyposis (FAP), respectively. However, only a small percentage of the population are carriers of these mutations [7,8]. On the other hand, somatic mutations in p53, APC and KRAS have no real prognostic value in cases of sporadic colorectal cancer [6]. Nevertheless, some clinical use might come from mutations in KRAS. They have recently been shown to be involved in the response of CRCs to cetuximab, suggesting a better response of patients without KRAS mutations in CRCs [9,10]. This shows that several steps in CRC development might be bypassed by other as yet unknown genetic events that lead towards CRC. We therefore wanted to improve our understanding of the genetic mechanisms of CRC development. In turn, this might identify new potential tumour markers useful for clinical practice.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Samples
###end title 13
###begin p 14
###xml 960 961 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 945 952 <span type="species:ncbi:9606">patient</span>
Sixteen samples of colorectal adenocarcinoma (CRC) and corresponding normal tissue were collected at the Department for Surgery at Jesenice hospital. Samples were stabilized in RNAlater (Ambion, USA) solution immediately after extraction. Samples were incubated at 4degreesC overnight and stored at -20degreesC, according to the manufacturer's recommendations. The study was approved by the National Medical Ethics Committee of the Republic of Slovenia. All 16 samples were evaluated by an expert pathologist at the Institute of Pathology, Faculty of Medicine, University of Ljubljana. Adjacent to samples stored in RNAlater tissue sections were obtained for histological evaluation. Only samples including within the range of 60% to 90% of invasive tumour cells were accepted for further analysis. Corresponding normal tissue samples contained no cancer cells as evaluated by pathologist. Tumour stage and nodal status were determined for each patient (Table 1).
###end p 14
###begin p 15
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Samples, histology and presence of activating KRAS mutations
###end p 15
###begin p 16
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
The table shows sample histological data and the presence of activating KRAS mutations. No activating KRAS mutations were found in corresponding normal tissue.
###end p 16
###begin p 17
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
T = tumour stage, N = nodal status, KRAS status - presence or absence of activating KRAS mutations.
###end p 17
###begin title 18
DNA extraction
###end title 18
###begin p 19
DNA from tissue stabilized in RNAlater (Ambion, USA) was isolated with a QIAgen kit (QIAgen) according to the manufacturer's instructions.
###end p 19
###begin title 20
RNA extraction
###end title 20
###begin p 21
RNA from tissue was isolated using TRI REAGENTtrade mark (Sigma Aldrich) and the PureLinkTM Micro-to-Midi Total RNA Purification System (Invitrogen), according to the manufacturer's instructions. Briefly, 50 - 100 mg of tissue was homogenized in TRI REAGENTtrade mark using PT 3100 homogenizer (Polytron). The homogenate was centrifuged at 12000 x g for 10 min at 4degreesC to remove insoluble material and the supernatant was transferred to a fresh microcentrifuge tube. Samples were allowed to sit at room temperature for 5 min, and 0.2 ml of chloroform was added per 1 ml of TRI REAGENTtrade mark. Samples were mixed by hand for 15 s and allowed to stand for 2 - 15 min at room temperature. The resulting mixture was centrifuged at 12000 x g for 15 min at 4degreesC. The aqueous phase was transferred to a fresh microcentrifuge tube and an equal amount of 70% ethanol was added. Samples were transferred to a PureLinkTM Micro-to-Midi Total RNA Purification System column (Invitrogen) and processed according to the manufacturer's protocol. All samples were washed from the column with 75 mul of RNAse free water.
###end p 21
###begin title 22
Analysis of RNA
###end title 22
###begin p 23
The quality of RNA was checked on a Bioanalyzer 2100 (Agilent) using an RNA 6000 Nano Labchip (Agilent) and a 6000 RNA ladder as reference (Ambion). The concentration and quantity of RNA was determined with ND-1000 (Nanodrop, USA).
###end p 23
###begin title 24
Preparation of aaRNA
###end title 24
###begin p 25
Preparation of aaRNA was performed with an Amino Allyl MessageAmptrade mark II aRNA Amplification Kit (Ambion) according to the manufacturer's recommendations. For each hybridization, we labelled 5 mug of normal (Cy3) and 5 mug of tumour (Cy5) mRNA. After removing the excess dye, the RNAs were dissolved in Nexterion Hybridization solution (Schott Nexterion).
###end p 25
###begin title 26
Microarrays
###end title 26
###begin p 27
###xml 31 36 <span type="species:ncbi:9606">Human</span>
###xml 63 68 <span type="species:ncbi:9606">Human</span>
Microarrays were prepared with Human Apoptosis Subset v2.0 and Human Cancer Subset v3.0 (Operon) 70mer oligonucleotides and Nexterion 70mer Oligo Microarraying Kit (Schott Nexterion) slides. Oligonucleotides were spotted using an MG1000 spotter (MicroGrid), immobilised and stored according to the manufacturer's instructions (Schott Nexterion). All hybridisations were performed on HS400 (Tecan) according to the manufacturer's instructions (Schott Nexterion). We used an LS200 scanner (Tecan) at 6 mum resolution for scanning the microarrays.
###end p 27
###begin title 28
Real time PCR
###end title 28
###begin p 29
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 113 116 113 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 264 268 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 345 353 343 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 434 438 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 519 525 499 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 606 611 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 952 954 906 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 966 968 912 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 976 984 918 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T normal</sub>
###xml 991 999 929 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T tumour</sub>
###xml 1007 1009 941 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 1017 1019 947 949 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tx</sub>
###xml 1026 1033 952 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T GAPDH</sub>
###xml 731 736 <span type="species:ncbi:9606">Human</span>
We used Taqman Reverse transcription reagent (Applied Biosystems) for cDNA synthesis. Expression of the SLC26A3, DCN, CALM3 and TPM1 genes in tumour samples relative to their normal adjacent tissues was measured using quantitative real time PCR based on the TaqMan(R) fluorescence methodology. A ready mixture of probes and primers specific for SLC26A3 mRNA expression (Assay-on-Demandtrade mark, Hs00995363_m1 (Applied Biosystems)), DCN mRNA expression (Assay-on-Demandtrade mark, Hs00266491_m1 (Applied Biosystems)), CALM3 mRNA expression (Assay-on-Demandtrade mark, Hs00270914_m1 (Applied Biosystems)), TPM1 mRNA expression (Assay-on-Demandtrade mark, Hs00165966_m1 (Applied Biosystems)) and Pre-Developed TaqMan Assay Reagents Human GAPDH (20x) mRNA (Applied Biosystems) were used as the endogenous control gene. All measurements were done in triplicate. The relative quantification of mRNA levels of the target was determined using the DeltaDeltaCT (DeltaDeltaCT = DeltaCT normal-DeltaCT tumour; DeltaCT = DeltaCTx-DeltaCT GAPDH) method, unless stated otherwise.
###end p 29
###begin title 30
Copy number
###end title 30
###begin p 31
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 198 206 198 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 522 530 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 896 900 896 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 902 910 902 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 995 999 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 1001 1009 1001 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1013 1017 1013 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
Gene copy number was determined by using real time PCR based on the TaqMan fluorescence methodology. The assays, TaqMan RNase P Detection Reagents (Applied Biosystems) and Assay-by-Design for TPM1, SLC26A3 and DCN (Applied Biosystems) gene detection were performed according to the manufacturer's instructions. Assay-by-Design for the TPM1 gene contained the following primers and probe: forward primer: GGAAAGTACATATCTGGGAGAAGCA, reverse primer: TTCTTGATGGCGTCCATGGT, probe: FAM TCGCACTCCCGCTCCT. Assay-by-Design for the SLC26A3 gene contained the following primers and probe: forward primer: GCCACAGCCAACAGAAAAATCAAAAT, reverse primer: CCTCAAAAGCATTTGTAGAATACACTGG, probe: FAM CTGGCCACAATATAC. Assay-by-Design for the DCN gene contained the following primers and probe: forward primer: CTGATGACCGCGACTTCGA, reverse primer: CGAAGATGGCATTGACAGCG, probe: FAM CCCAGTGTGCCCCTTC. The copy numbers of TPM1, SLC26A3 and DCN genes were determined on the basis of the threshold cycle difference between TPM1, SLC26A3 and DCN and the RnaseP gene. For calculation of the copy number, combined_gene_copy_number_assay_macro-1.xls (Applied Biosystems) was used.
###end p 31
###begin title 32
KRAS mutation detection and V64L (rs17018909) detection
###end title 32
###begin p 33
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 441 445 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 844 849 835 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
The first exon of the KRAS gene of each tumour sample and corresponding normal tissue was amplified with PCR as previously described by Konig and co. [11]. Screening for changes in PCR products was performed with Single Stranded Conformation Analysis (SSCA) [12,13]. Samples showing different migration shifts were chosen for sequencing. All 16 corresponding normal tissues were also sequenced for V64L (C>A, rs17018909) polymorphism of the DCN gene, which might have an effect on performance of Hs00266491_m1 Assay-on-Demandtrade mark (Applied Biosystems). Sequencing was performed using BigDye Terminator Ready Reaction Mix. Sequences were purified, dissolved and analysed on an ABI PRISM 310 Genetic Analyzer according to the manufacturer's recommendations (Applied Biosystems, USA). Nucleotide sequences were compared against the published KRAS cDNA sequence (GenBank accession number ) in order to define the mutation.
###end p 33
###begin title 34
Data analysis
###end title 34
###begin p 35
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 701 705 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 707 714 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 716 720 716 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 987 992 987 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
We used ArrayPro Analyser (Media Cybernetic, USA) software for feature extraction after imaging. Acuity 4.0 (Molecular Devices, USA) was used for filtration of bad signals, Lowess normalization and microarray data analysis. We filtered out genes that were not expressed in all 16 samples and showed a median expression of 1.5 times. Results on differentially expressed genes were compared to 5 major expression studies available from the PubMed GEO project [14-18] and evidence of independent validation of gene expression data was checked using the PubMed database. All other statistical analyses were done using SPSS 16 (SPSS inc.). We used the paired t test to compare differences in the amount of TPM1, SLC26A3, DCN and CALM3 mRNA between CRC and corresponding normal tissue. The paired t test was also used to check the difference in GAPDH expression between corresponding normal tissue and tumour samples. The t test was also used to compare pairs of samples with mutations in the KRAS gene to pairs of samples without these mutations. P < 0.05 was considered statistically significant.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
The expression profiles of 16 primary human colorectal tumours were obtained by comparison of CRC mRNA with mRNA from their corresponding normal tissue on a 3060 element microarray from Operon. In our experimental design, microarrays were used as a dual colour system in which CRC and the corresponding normal mRNA were separately labelled, mixed and hybridised together on each array. The acquired data were analysed with Acuity 4.0 to select reliable data. Only genes present in all 16 microarrays were considered for further processing. Out of 3060 genes, 30 genes showed differential expression (see additional file 1[14-18]).
###end p 37
###begin p 38
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASP9</italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VIM</italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS4</italic>
###xml 215 218 215 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRI</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGP2</italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS3</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB</italic>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP2K7 </italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP2</italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB4</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3</italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EEF1A1</italic>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOX4A</italic>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH1</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRT19</italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA2</italic>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBI</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBL2</italic>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and TNA</italic>
###xml 505 510 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD022</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT</italic>
###xml 518 528 518 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and CARD10</italic>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPC1</italic>
###xml 596 600 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAI1</italic>
###xml 602 607 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TTYH1</italic>
###xml 650 656 650 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH12 </italic>
###xml 660 666 660 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMP22 </italic>
Because of the manageable number of differentially expressed genes, we crosschecked their expression to already existing microarray data (see additional file 1). Eleven out of 30 genes (SLC26A3, CASP9, VIM, LGALS4, SRI, UGP2, LGALS3, TPM1, TUBB, MAP2K7 and CRABP2) showed good concordance with multiple microarray expression studies. Ten out of 30 genes (ITGB4, CALM3, EEF1A1, HOX4A, PCDH1, KRT19, GATA2, TGFBI, RBL2, and TNA) showed variable expression between different studies. Interestingly, 3 genes (AD022, CORT, and CARD10) were not included in any of these studies and 4 genes (DCN, NPC1, RAI1, TTYH1) were characterised in only 1 study. Only CDH12 and PMP22 showed a difference between multiple expression studies and our results. In order to enable other users comprehensively to interpret and evaluate our results, original tables of complete microarray results are available in the supplementary data (see the GEO website at  Series entry: GSE14010).
###end p 38
###begin title 39
Real time PCR
###end title 39
###begin p 40
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
Relative quantification real-time PCR was used to determine the difference in expression of SCL26A3, DCN, TPM1 and CALM3 between CRC and corresponding normal tissue (Figure 1). We used GAPDH as endogenous control for normalization. No statistically significant difference in expression of GAPDH between corresponding normal tissue and tumour samples was detected (paired t test p = 0,113). These genes were chosen because they have been shown to play a significant role in CRC development. They also showed good concordance with other microarray studies and no precise quantification of their mRNA has yet been performed.
###end p 40
###begin p 41
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Significant under-expression of <italic>SLC26A3</italic>, <italic>DCN</italic>, <italic>CALM3 </italic>and <italic>TPM1 </italic>in tumour in comparison to normal tissue</bold>
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 138 141 138 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 255 257 251 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 285 287 277 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 323 330 315 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 332 335 324 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 337 343 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 347 352 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 383 385 371 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
Significant under-expression of SLC26A3, DCN, CALM3 and TPM1 in tumour in comparison to normal tissue. Average expression of the SLC26A3, DCN, CALM3 and TPM1 gene was significantly lower in CRC in comparison to normal tissue. Expression is shown in DeltaCT units, whereby larger DeltaCT value represents down-regulation of SLC26A3, DCN, CALM3 and TPM1 in comparison to smaller DeltaCT of normal tissue.
###end p 41
###begin p 42
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 130 137 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 139 142 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 330 338 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 801 808 801 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> CALM3 </italic>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 915 921 915 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 953 958 953 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1006 1007 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1281 1286 1281 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
Figure 1 shows the relative average expression of genes in comparison to normal tissue (Figure 1). In agreement with microarrays, SLC26A3, DCN, CALM3 and TPM1 showed clear downregulation. SLC26A3 was downregulated in 13 out of 16 cases (Figure 2). Two cases showed overexpression and 1 case showed almost no change in expression. SLC26A3 had 12.43 times lower expression in CRC in comparison to normal tissue (p < 0.003). DCN was under- and overexpressed in 14 and 2 cases of CRC in comparison to normal tissue, respectively (Figure 2). CRC had on average 4.61 times less DCN than normal tissue (p < 0.007). We also report that we did not detect V64L polymorphism in 16 corresponding normal tissues, so no adverse effects on performance of real-time PCR was expected, as suggested by the manufacturer. CALM3 showed underexpression in 11 and no change in 5 cases of CRC (Figure 2). CRC had on average 1.7 times less CALM3 than normal tissue (p < 0.003). TPM1 was underexpressed in 9 out of 16 cases (Figure 2). In only 1 case was TPM1 overexpressed in CRC in comparison to normal tissue. The remaining samples showed no major difference. TPM1 was on average 1.6 times lower in CRC that normal tissue (p < 0.015). However, when considering only downregulated samples, 2.5 times less TPM1 mRNA was found in CRC in comparison to normal tissue.
###end p 42
###begin p 43
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>SLC26A3</italic>, <italic>DCN</italic>, <italic>CALM3 </italic>and <italic>TPM1 </italic>in 16 CRC in comparison to normal tissue</bold>
###xml 119 121 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 158 160 142 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
Expression of SLC26A3, DCN, CALM3 and TPM1 in 16 CRC in comparison to normal tissue. Expression is shown in DeltaDeltaCT units, whereby a negative DeltaDeltaCT value represents down-regulation of gene in CRC in comparison to corresponding normal tissue. Positive bar represents over-expression of gene in CRC in comparison to corresponding normal tissue.
###end p 43
###begin title 44
Copy number
###end title 44
###begin p 45
###xml 8 15 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 423 431 423 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
So far, SLC26A3, DCN and TPM1 genes have been suggested to have tumour suppressor properties. We investigated the possibility that loss of alleles could be present in the location of genes to contribute to underexpression or inactivation of the mentioned genes. We used the real time PCR method to evaluate the amount of allele present in each sample. Interestingly, although we did not find any allele loss at the site of SLC26A3 and DCN genes, we detected 1 loss of the TPM1 allele in 16 samples of CRC (data not shown).
###end p 45
###begin title 46
Mutation detection
###end title 46
###begin p 47
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 700 704 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 749 754 749 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 872 877 872 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 962 967 962 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 999 1004 999 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1033 1034 1033 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
In order to detect mutations, we used the SSCA method for preliminary testing and automatic sequencing for subsequent confirmation of different patterns. We searched for mutations in codon 12 and 13, since these mutations represent 96 - 99% of all mutations detected in CRC. Mutations in other positions, such as 66 and 146, account for around 1-4% of all mutations, although their clinical relevance in CRC is unclear [19]. We found activating mutations in codon 12 and 13 in 8 out of 16 samples (Table 1). No activating KRAS mutations were found in corresponding normal tissue. When comparing the expression difference between normal and tumour samples, we found significant underexpression of the DCN gene in the group of tumours with activating KRAS mutations in comparison with tumours without these mutations (p < 0.05). We also found no change in expression of the TPM1 gene in CRC cases with a mutation in KRAS, in comparison with underexpression of the TPM1 gene in CRCs without activating KRAS mutations (p < 0,05) (Figure 3).
###end p 47
###begin p 48
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>DCN </italic>and <italic>TPM1 </italic>in pairs of samples with a different <italic>KRAS </italic>status</bold>
###xml 111 113 103 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 150 152 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 188 191 172 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 193 198 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 279 284 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Expression of DCN and TPM1 in pairs of samples with a different KRAS status. Expression is shown in DeltaDeltaCT units, whereby a negative DeltaDeltaCT value represents down-regulation of DCN, TPM1 in comparison to normal tissue. Pairs of samples were grouped according to their KRAS status.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 138 141 138 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1202 1203 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
Major molecular pathways involved in the development of colorectal cancer have been identified [4]. However, major genes, such as p53 and APC, involved in these pathways have shown only limited value in clinical use [6]. Moreover, only a minority of CRCs possess a full complement of these molecular abnormalities [5]. This shows that several steps in CRC development might be bypassed by other as yet unknown genetic events that lead towards CRC. Using expression profiling, we set out to identify genes that may play an important role in the development of CRC, whose expression has not yet been characterized. This is also the first study performed on a cohort of Slovenian patients on this scale. We were able to identify 30 differentially expressed genes (see additional file 1). When comparing the obtained results with other studies, only 2 genes showed a large difference in expression in comparison to our study. It is noteworthy that 10 out of 30 genes showed variable expression between studies. Even more interesting was the fact that we were able to find better characterisation of expression with other methods than microarrays for only 7 of 30 genes for CRC samples (see additional file 1). These two observations show the need to characterise expression further with other, more precise methods, such as real time PCR.
###end p 50
###begin p 51
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASP9</italic>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VIM</italic>
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS4</italic>
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRI</italic>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGP2</italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS3</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP2K7</italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP2</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAI1 </italic>
###xml 349 356 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 368 371 368 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
In the group of genes showing good concordance with other microarray studies were SLC26A3, CASP9, VIM, LGALS4, SRI, UGP2, LGALS3, TPM1, TUBB, MAP2K7, and CRABP2. DCN and RAI1 also showed concordance with our results, although their expression was characterised in only one study. When we looked for the function of these genes, we found that three (SLC26A3, TPM1, and DCN) of them play a tumour suppressor role. Moreover, no precise expression analysis on clinical cases of CRC exists to confirm their involvement. TPM1 and DCN are also related to the KRAS signalling pathway, suggesting that their expression might change due to the presence or absence of activating KRAS mutations in codon 12 and 13. Moreover, the expression of none of the three genes has so far been characterised with real time PCR in samples of CRC.
###end p 51
###begin p 52
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 367 375 367 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 476 483 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 612 620 612 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 792 800 792 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 879 887 879 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1011 1019 1011 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1312 1320 1312 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1375 1383 1375 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1640 1647 1640 1647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 1669 1677 1669 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 1803 1811 1803 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 264 272 <span type="species:ncbi:9606">Patients</span>
The SLC26A3 gene encodes anion transporter expressed in mucosa of the lower gastrointestinal tract [20]. Mutations in the SLC26A3 gene cause congenital chloride diarrhea (CLD) [21]. This rare condition is attributed to a lack of chlorine uptake in the colon [22]. Patients with CLD also have a higher risk of developing CRC [23]. Chapman et al also demonstrated that SLC26A3 possesses a tumour suppressor ability by inhibiting cell growth in cells transfected with functional SLC26A3. Moreover, they showed that the tumour suppressor role is separated from the role of anion transporter [24]. This suggests that SLC26A3 is not downregulated as a result of transition of normal colon mucosa towards CRC, but plays an active role in CRC development. The few studies investigating expression of SLC26A3 so far have only used subtractive hybridization and northern blot to show that SLC26A3 is downregulated in adenomas of colon. Using northern blot analysis, Anthalis et al. observed progressive downregulation of SLC26A3 from normal mucosa to polyp and finally to CRC [25]. These methods are not as precise as the real time PCR method used in this study, which provides more accurate and reproducible quantification with a larger dynamic range. In agreement with above mentioned data, we report underexpression of SLC26A3 in CRC in comparison with corresponding normal tissue. SLC26A3 mRNA was on average 12.4 times underexpressed (p < 0.01) in CRC than normal surrounding mucosa. Because abnormalities of chromosome 7 have been associated with colorectal carcinoma, we also hypothesised that loss of alleles might lead to underexpression of SLC26A3. However, no loss of SLC26A3 was detected using the real-time PCR methodology, showing that some other mechanism must be involved in downregulation of the SLC26A3 gene.
###end p 52
###begin p 53
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 984 986 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1248 1250 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1405 1409 1402 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 1658 1662 1655 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 1691 1696 1688 1693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1781 1786 1778 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1833 1837 1830 1834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 1904 1908 1901 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 2093 2097 2090 2094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 2152 2157 2149 2154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 2168 2170 2165 2167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2393 2395 2387 2389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2597 2601 2591 2595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 2750 2754 2744 2748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 196 211 <span type="species:ncbi:10029">Chinese hamster</span>
Decorin is a member of the small leucine-rich proteoglycan gene family. Implication of decorin in the regulation of cell cycle has been suggested by numerous studies. Overexpression of decorin in Chinese hamster ovary cells inhibits cell proliferation [26]. Santra et al. showed that de novo expression of decorin leads to an arrest of transformed cells in the G1 phase of the cell cycle. Moreover, they were able to restore growth by blocking decorin transcription via aDcns [27]. The tumour suppressor activity of decorin is mediated through various pathways. Seidler and co. showed that decorin causes a reduction of activity and decline in total EGFR in tumour cells. Moreover, the same group showed that decorin also activates caspase-3, the key enzyme in apoptosis [28]. Decorin causes the induction of p21, which in turn leads to growth suppression [29]. Decorin also has binding sites for TGF-beta, through which it apparently modulates the action of this important citokine [30]. Interestingly, although many tumour suppressor effects have been associated with decorin, no precise quantification by real time PCR has been performed. However, decorin protein under-expression in CRC has been clearly established using immunohistochemistry [31]. We are the first to report and characterise decorin expression on the mRNA level using a real-time PCR quantification method. Our results show that the DCN gene is 4.6 times (p < 0.01) underexpressed in tumour than normal tissue. However, in two CRC samples we found decorin overexpression in comparison to normal tissue. Because Decorin acts through EGFR, we speculated that we might see a difference in DCN expression between CRCs with KRAS mutations and CRCs without them. We found that CRCs with activating mutations in the KRAS gene showed much larger underexpression of the DCN gene in comparison to normal tissue than CRCs without mutations in KRAS. In the Fearon and Vogelstein model, activating KRAS mutations are one of the first genomic events leading to the development of CRC. This in turn suggests that underexpression of the DCN gene might be early consequence of acquired activating KRAS mutations [32]. Moreover, as reported previously, overexpression of decorin also plays a role in TGF-beta by inhibiting its synthesis and bioactivity, thus entering another important CRC development pathway as a tumour suppressor gene [30]. The importance of decorin downregulation for the development of CRC is further emphasized by its downregulation despite the absence of activating KRAS mutations. Lastly, we found no deletions of the DCN gene using the real-time PCR method, showing that either methylation of promoter or suppression by trans-activating elements must be responsible for DCN underexpression in a tumour.
###end p 53
###begin p 54
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 710 715 710 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 930 935 930 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 993 998 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1050 1055 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1112 1117 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1253 1258 1253 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1305 1310 1305 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1439 1444 1439 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1503 1508 1503 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1619 1624 1619 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 1726 1731 1726 1731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 266 271 <span type="species:ncbi:9606">human</span>
Tropomyosines are important actin binding proteins. The actin cytoskeleton plays an important role in regulation of cell proliferation, apoptosis, cell migration, invasion and anchorage independent growth [33]. Tropomysine 1 is consistently abolished in a number of human cancer cell lines and tissues [34,35]. Moreover, it has been demonstrated that tropomysin 1 (TPM1) has tumour suppressor properties [36] and it can revert transformed phenotype [37]. Despite the obvious importance of TPM1 in tumour development, data on TPM1 gene expression in clinical samples of CRC samples in comparison to corresponding normal tissue do not exist. Our data obtained by real-time PCR show 1.6 times lower expression of TPM1 in CRCs, which supports the current view of TPM1 as a tumour suppressor. TPM1 was underexpressed in 9 out of 16 cases, in 6 samples no major difference between CRC and normal tissue was found and in 1 case we found TPM1 overexpression. More interesting was the observation that TPM1 was much more underexpressed in CRCs not harbouring KRAS mutations in comparison to normal tissue. In CRCs with a KRAS mutation, we found almost no difference in expression to normal tissue. This observation suggests the conclusion that downregulation of TPM1 is independent of the constitutively activated KRAS pathway. This is also in agreement with the observation that epigenetic factors such as methylation of the promoter region cause TPM1 downregulation. Moreover, we also report identification of TPM1 gene loss in 1 CRC, showing that loss of genetic material could also be responsible for underexpression of the TPM1 gene. This is in agreement with the hypothesis that epigenetic and genetic events are responsible for TPM1 downregulation, rather than inhibition by trans acting elements.
###end p 54
###begin p 55
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 981 987 981 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM1 </italic>
###xml 991 997 991 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM2 </italic>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1402 1404 1402 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1678 1680 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1681 1683 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
One of the interesting results from microarrays was underexpression of the CALM3 gene, which codes for calmodulin protein. Since expression of calmodulin 3 was variable among different microarray studies (see additional file 1) we validated our result with real-time PCR and confirmed the observed underexpression of CALM3 in CRC. However, this result is in contrast with its proposed cell cycle promotion role, which is reflected by the arrest of the mitotic cycle by anti-CaM drugs added to a wide variety of cells [38]. Moreover, addition of monoclonal antibody against CaM inhibited DNA synthesis and progression through G1, and mitosis exit was sensitive to intracellular concentrations of CaM [39]. Calmodulin in higher vertebrates is encoded by three genes, although all three genes code for an identical calmodulin protein consisting of 148 amino acids [40]. This raises the question of whether the other two CALM genes are expressed in a different way. Surprisingly, both CALM1 and CALM2 showed significant underexpression, as reported by various microarray studies [14-17]. This observation supports the hypothesis proposed by Kahl and Means that cancer cells containing a disruption in the cyclin D/cdk4 7 pRb regulatory pathway, may no longer require Ca2+/CaM to regulate the activation of this pathway because it is already activated or unnecessary for G1 progression in the tumour cells [38]. One other possible explanation of such a result is that the position in the cell rather than the amount of calmodulin is enough to promote cell cycle. The cell could achieve this positioning of calmodulin by targeting CALM mRNAs to a different intracellular compartment [41,42].
###end p 55
###begin title 56
Conclusion
###end title 56
###begin p 57
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1</italic>
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALM3 </italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 461 465 461 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 469 477 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC26A3 </italic>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 595 600 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPM1 </italic>
###xml 778 782 778 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 819 824 819 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 849 853 849 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 906 911 906 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
In conclusion, we detected significant under-expression of genes SLC26A3, TPM1, DCN and CALM3 in CRC, providing further evidence of their decreased mRNA expression and thus implicating them in the development of this type of cancer. We also described a correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC. When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case of CRC, and no deletions of DCN and SLC26A3 were found. Moreover, we found underexpression of the TPM1 gene in cases of CRCs without KRAS mutations, showing that TPM1 might serve as an alternative path of development of CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the other hand, the correlation of DCN underexpression with the presence of KRAS mutations, suggests that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount of the important tumour suppressor protein decorin.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
VM carried out the analysis of KRAS mutations, real-time PCR and wrote and prepared the manuscript. VM and GB carried out microarray and statistical analysis and participated in the design of the study. ZS and MR did the surgery and obtained samples and informed consents from patients. MV helped with pathological evaluation of tissue samples and histological staging. DG conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 61
###begin title 62
Pre-publication history
###end title 62
###begin p 63
The pre-publication history for this paper can be accessed here:
###end p 63
###begin p 64

###end p 64
###begin title 65
Supplementary Material
###end title 65
###begin title 66
Additional file 1
###end title 66
###begin p 67
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 2 Differentially expressed genes in 16 colorectal cancers in direct comparison to corresponding normal tissue</bold>
Table 2 Differentially expressed genes in 16 colorectal cancers in direct comparison to corresponding normal tissue. The column, Independent validation, contains the result of a search for articles describing particular gene expression on the level of mRNA in CRC, done with methods other than microarray. References 14-18 were used to compare gene expression.
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
This work was supported by the Slovenian Research Agency (ARRS) (Program P3-054). This work is a part of the PhD thesis of candidate Vid Mlakar, BSc of Microbiology.
###end p 70
###begin article-title 71
Cancer statistics, 2005
###end article-title 71
###begin article-title 72
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
###end article-title 72
###begin article-title 73
Colorectal carcinogenesis: Road maps to cancer
###end article-title 73
###begin article-title 74
Genomic instability and colon cancer
###end article-title 74
###begin article-title 75
Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer
###end article-title 75
###begin article-title 76
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
###end article-title 76
###begin article-title 77
The ABC of APC
###end article-title 77
###begin article-title 78
Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome)
###end article-title 78
###begin article-title 79
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
###end article-title 79
###begin article-title 80
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
###end article-title 80
###begin article-title 81
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe
###end article-title 81
###begin article-title 82
Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene
###end article-title 82
###begin article-title 83
Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations
###end article-title 83
###begin article-title 84
Whole genome analysis for liver metastasis gene signatures in colorectal cancer
###end article-title 84
###begin article-title 85
Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays
###end article-title 85
###begin article-title 86
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays
###end article-title 86
###begin article-title 87
Deciphering cellular states of innate tumor drug responses
###end article-title 87
###begin article-title 88
Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon
###end article-title 88
###begin article-title 89
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
###end article-title 89
###begin article-title 90
Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas
###end article-title 90
###begin article-title 91
Mutations of the Down-regulated in adenoma (DRA) gene cause congenital chloride diarrhoea
###end article-title 91
###begin article-title 92
Genetic Disorders of Membrane Transport III. Congenital chloride diarrhea
###end article-title 92
###begin article-title 93
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene
###end article-title 93
###begin article-title 94
The colon anion transporter, down-regulated in adenoma, induces growth suppression that is abrogated by E1A
###end article-title 94
###begin article-title 95
Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression
###end article-title 95
###begin article-title 96
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 36 51 <span type="species:ncbi:10029">Chinese hamster</span>
Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation
###end article-title 96
###begin article-title 97
###xml 70 75 <span type="species:ncbi:9606">human</span>
De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells
###end article-title 97
###begin article-title 98
Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation
###end article-title 98
###begin article-title 99
Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases
###end article-title 99
###begin article-title 100
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth
###end article-title 100
###begin article-title 101
Immunohistochemical study of decorin expression in polyps and carcinomas of the colon
###end article-title 101
###begin article-title 102
Molecular interactions in the Vogelstein model of colorectal carcinoma
###end article-title 102
###begin article-title 103
Rho GTPases in transformation and metastasis
###end article-title 103
###begin article-title 104
###xml 16 21 <span type="species:ncbi:9606">human</span>
Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines
###end article-title 104
###begin article-title 105
###xml 45 50 <span type="species:ncbi:9606">human</span>
Two differentially expressed genes in normal human prostate tissue and in carcinoma
###end article-title 105
###begin article-title 106
Anti-oncogenic effects of tropomyosin: isoform specificity and importance of protein coding sequences
###end article-title 106
###begin article-title 107
Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene
###end article-title 107
###begin article-title 108
Regulation of cell cycle progression by calcium/calmodulin-dependent pathways
###end article-title 108
###begin article-title 109
Calmodulin-mediated cell cycle regulation: new mechanisms for old observations
###end article-title 109
###begin article-title 110
Calmodulin, and various ways to regulate its activity
###end article-title 110
###begin article-title 111
Differential calmodulin gene expression in the rodent brain
###end article-title 111
###begin article-title 112
The calmodulin multigene family as a unique case of genetic redundancy: multiple levels of regulation to provide spatial and temporal control of calmodulin pools?
###end article-title 112

